SC 13D/A | 2019-06-04 | BAUPOST GROUP LLC/MA | Orexigen Therapeutics, Inc. | 0 | 0.0% | EDGAR |
SC 13G/A | 2019-02-14 | BIOTECHNOLOGY VALUE FUND L P | Orexigen Therapeutics, Inc. | 1,687,702 | 8.3% | EDGAR |
SC 13G/A | 2019-02-14 | Telemetry Investments, L.L.C. | Orexigen Therapeutics, Inc. | 1,295,844 | 6.4% | EDGAR |
SC 13G/A | 2019-02-12 | Nineteen77 Global Multi-Strategy Alpha Master Ltd | Orexigen Therapeutics, Inc. | 2,096,227 | 10.0% | EDGAR |
SC 13G/A | 2019-02-12 | UBS OCONNOR LLC | Orexigen Therapeutics, Inc. | 2,096,227 | 10.0% | EDGAR |
SC 13G/A | 2019-02-11 | Man Group plc | Orexigen Therapeutics, Inc. | 0 | 0.0% | EDGAR |
SC 13D/A | 2018-10-31 | BAUPOST GROUP LLC/MA | Orexigen Therapeutics, Inc. | 11,332,219 | 37.5% | EDGAR |
SC 13D/A | 2018-10-26 | BAUPOST GROUP LLC/MA | Orexigen Therapeutics, Inc. | 10,404,416 | 37.5% | EDGAR |
SC 13D/A | 2018-04-26 | BAUPOST GROUP LLC/MA | Orexigen Therapeutics, Inc. | 9,996,116 | 37.5% | EDGAR |
SC 13G/A | 2018-02-14 | Telemetry Investments, L.L.C. | Orexigen Therapeutics, Inc. | 1,255,061 | 6.3% | EDGAR |
SC 13G/A | 2018-02-13 | Foresite Capital Fund II, L.P. | Orexigen Therapeutics, Inc. | 0 | 0.0% | EDGAR |
SC 13G | 2018-02-13 | UBS OCONNOR LLC | Orexigen Therapeutics, Inc. | 2,079,808 | 10.0% | EDGAR |
SC 13G | 2018-02-12 | Nineteen77 Global Multi-Strategy Alpha Master Ltd | Orexigen Therapeutics, Inc. | 2,079,808 | 10.0% | EDGAR |
SC 13G/A | 2018-02-09 | Man Group plc | Orexigen Therapeutics, Inc. | 1,524,143 | 8.1% | EDGAR |
SC 13G | 2017-12-01 | Man Group plc | Orexigen Therapeutics, Inc. | 1,600,000 | 8.5% | EDGAR |
SC 13G/A | 2017-08-10 | Telemetry Investments, L.L.C. | Orexigen Therapeutics, Inc. | 1,234,339 | 7.6% | EDGAR |
SC 13G | 2017-08-03 | Telemetry Investments, L.L.C. | Orexigen Therapeutics, Inc. | 1,234,339 | 7.6% | EDGAR |
SC 13G/A | 2017-02-14 | Foresite Capital Fund II, L.P. | Orexigen Therapeutics, Inc. | 174,373 | 1.2% | EDGAR |
SC 13G | 2016-07-19 | BIOTECHNOLOGY VALUE FUND L P | Orexigen Therapeutics, Inc. | 1,059,042 | 6.9% | EDGAR |
SC 13D/A | 2016-07-12 | BAUPOST GROUP LLC/MA | Orexigen Therapeutics, Inc. | 7,397,965 | 37.5% | EDGAR |